Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

• Amit Dutt ,

  * E-mail: matthew_meyerson@dfci.harvard.edu (MM); adutt@actrec.gov.in (AD)

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Kharghar, Navi Mumbai, India

  ⨯
• Alex H. Ramos,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America, Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Peter S. Hammerman,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Craig Mermel,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Jeonghee Cho,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Tanaz Sharifnia,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Ajit Chande,

  Affiliation Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Kharghar, Navi Mumbai, India

  ⨯
• Kumiko Elisa Tanaka,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Nicolas Stransky,

  Affiliation The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Heidi Greulich,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Nathanael S. Gray,

  Affiliations Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Matthew Meyerson

  * E-mail: matthew_meyerson@dfci.harvard.edu (MM); adutt@actrec.gov.in (AD)

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯